Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
HU Group Holdings Inc (H.U. Group) is a holding company that specializes in providing lab testing and related services, in vitro diagnostics, and healthcare-related services. The company develops, manufactures and sells and rents diagnostic products that are used in the medical field for early detection and diagnosis. Its products and services encompass lab testing solutions, diagnostic tools, and healthcare services. H.U. Group's clinical laboratory testing services include collecting consigned specimens of patients from medical institutions, conducting analyses and reporting the test results back. The company provides various healthcare-related services, such as sterilization, clinical trial support and preventive medicine-related services. It offers sterilization services to hospitals in the Kanto, Kansai, Chugoku and Kyushu regions. H.U.Group is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Akasaka Intercity AIR, 1-8-1, Akasaka, Minato, Tokyo, 107-0052
Website
www.hugp.com
Telephone
81 3 62790801
No of Employees
5,157
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4544 (TYO)
Revenue (2025)
$1.6B
1.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
147.2%
(2025 vs 2024)
Market Cap*
$1.2B
Net Profit Margin (2025)
XYZ
142.1%
(2025 vs 2024)
* As of and is in US$
HU Group Holdings Inc premium industry data and analytics
Products and Services
| Services |
|---|
| LTS (Lab Testing Services) |
| Healthcare Related Services |
| Clinical Laboratory Testing Services |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In September, the company entered into an agreement to sell an 80% stake in Carelex Co., Ltd. to Wakita & Co. Ltd. |
| 2025 | New Products/Services | In June, the company and Fujirebio launched the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE G immunoassay analyzers. |
| 2024 | Contracts/Agreements | In January, Fujirebio entered into an agreement with Agappe Diagnostics to provide the equipment for CLIA system reagents manufacturing project. |
Competitor Comparison
| Key Parameters | HU Group Holdings Inc | Alfresa Holdings Corp | Soiken Holdings Inc | Corin Japan KK | Toho Pharmaceutical Co., Ltd. |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Minato | Chiyoda-Ku | Toyonaka | Osaka | Tokyo |
| State/Province | Tokyo | Tokyo | Osaka | Osaka | Tokyo |
| No. of Employees | 5,157 | 12,525 | 81 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shigekazu Takeuchi | Chairman; Chief Executive Officer; President | Executive Board | 2020 | - |
| Tadashi Hasegawa | Executive Officer; President’s Special Assignments Officer | Senior Management | 2020 | - |
| Goki Ishikawa | Managing Executive Officer | Senior Management | 2020 | - |
| Makoto Matsumoto | Managing Executive Officer | Senior Management | 2023 | - |
| Takayuki Yoshizumi | Executive Officer-Human Resources and General Affairs | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer